AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 OCT 4 - (NewsRx.com & NewsRx.net) --
Ribozyme Pharmaceuticals, Inc., (RPI) (RZYM) announced the start of a new Phase I clinical trial relating to the safety and pharmacokinetics of its innovative compound Herzyme.
Herzyme is an anti-human epidermal growth factor receptor type 2 (HER2) ribozyme that is being developed through RPI's strategic collaboration with Elan Corporation (Medizyme Pharmaceuticals, Ltd.). Elan and RPI are planning to develop Herzyme for treatment of breast and ovarian cancer in conjunction with Elan's proprietary Medipad Drug Delivery system.
"The initiation of this trial in conjunction with our partner Elan, marks another key step toward development of ribozyme-based therapies for treatment of cancer," said Howard W. Robin, RPI. "Herzyme may provide an important approach in the treatment of cancers that over express the HER2 oncogene."
The ...